🎉 M&A multiples are live!
Check it out!

Janux Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Janux Therapeutics and similar public comparables like Galapagos, Benevolent AI, and Pharming.

Janux Therapeutics Overview

About Janux Therapeutics

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.


Founded

2017

HQ

United States of America
Employees

81

Website

januxrx.com

Financials

LTM Revenue $8.2M

LTM EBITDA -$106M

EV

$709M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Janux Therapeutics Financials

Janux Therapeutics has a last 12-month revenue of $8.2M and a last 12-month EBITDA of -$106M.

In the most recent fiscal year, Janux Therapeutics achieved revenue of $10.6M and an EBITDA of -$96.8M.

Janux Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Janux Therapeutics valuation multiples based on analyst estimates

Janux Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $8.1M $10.6M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$71.0M -$96.8M XXX XXX XXX
EBITDA Margin -879% -914% XXX XXX XXX
Net Profit -$63.1M -$58.3M XXX XXX XXX
Net Margin -780% -551% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Janux Therapeutics Stock Performance

As of April 15, 2025, Janux Therapeutics's stock price is $29.

Janux Therapeutics has current market cap of $1.7B, and EV of $709M.

See Janux Therapeutics trading valuation data

Janux Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$709M $1.7B XXX XXX XXX XXX $-1.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Janux Therapeutics Valuation Multiples

As of April 15, 2025, Janux Therapeutics has market cap of $1.7B and EV of $709M.

Janux Therapeutics's trades at 86.1x LTM EV/Revenue multiple, and -6.7x LTM EBITDA.

Analysts estimate Janux Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Janux Therapeutics and 10K+ public comps

Janux Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $709M XXX XXX XXX
EV/Revenue 67.0x XXX XXX XXX
EV/EBITDA -7.3x XXX XXX XXX
P/E -24.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -16.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Janux Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Janux Therapeutics Valuation Multiples

Janux Therapeutics's NTM/LTM revenue growth is -52%

Janux Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.4M for the same period.

Over next 12 months, Janux Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Janux Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Janux Therapeutics and other 10K+ public comps

Janux Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 31% XXX XXX XXX XXX
EBITDA Margin -914% XXX XXX XXX XXX
EBITDA Growth 36% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -966% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 388% XXX XXX XXX XXX
R&D Expenses to Revenue 646% XXX XXX XXX XXX
Opex to Revenue 1034% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Janux Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Janux Therapeutics M&A and Investment Activity

Janux Therapeutics acquired  XXX companies to date.

Last acquisition by Janux Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Janux Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Janux Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Janux Therapeutics

When was Janux Therapeutics founded? Janux Therapeutics was founded in 2017.
Where is Janux Therapeutics headquartered? Janux Therapeutics is headquartered in United States of America.
How many employees does Janux Therapeutics have? As of today, Janux Therapeutics has 81 employees.
Who is the CEO of Janux Therapeutics? Janux Therapeutics's CEO is Dr. David Campbell, PhD.
Is Janux Therapeutics publicy listed? Yes, Janux Therapeutics is a public company listed on NAS.
What is the stock symbol of Janux Therapeutics? Janux Therapeutics trades under JANX ticker.
When did Janux Therapeutics go public? Janux Therapeutics went public in 2021.
Who are competitors of Janux Therapeutics? Similar companies to Janux Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Janux Therapeutics? Janux Therapeutics's current market cap is $1.7B
What is the current revenue of Janux Therapeutics? Janux Therapeutics's last 12-month revenue is $8.2M.
What is the current EBITDA of Janux Therapeutics? Janux Therapeutics's last 12-month EBITDA is -$106M.
What is the current EV/Revenue multiple of Janux Therapeutics? Current revenue multiple of Janux Therapeutics is 86.1x.
What is the current EV/EBITDA multiple of Janux Therapeutics? Current EBITDA multiple of Janux Therapeutics is -6.7x.
What is the current revenue growth of Janux Therapeutics? Janux Therapeutics revenue growth between 2023 and 2024 was 31%.
Is Janux Therapeutics profitable? Yes, Janux Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.